TriSalus Life Sciences, Inc. Common Stock

Day range

$3.53 – $3.81

Open

$3.62

Prev close

$3.59

Volume

59.8K

Market cap

$221.05M

Shares out

61.57M

P/E

—

P/S

4.90

P/B

33.75

P/FCF

—

ROE

-895.8%

ROA

-94.0%

Debt/Equity

5.05

Div yield

0.00%

As of Oct 23, 2026

• Regulatory decisionSep 22, 2026

  On September 22, 2026, TriSalus Life Sciences, Inc. (the "Company") issued a press release announcing that it has received U.S. Food and Drug Administration ("FDA") 510(k) clearance for its TriNav Advance device.

• Annual meeting resultsMay 14, 2026

  On May 14, 2026, TriSalus Life Sciences, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Meeting"). A total of 41,728,676 shares of our Common Stock, or 67.9% of the total outstanding shares, of our Common Stock were represented at the Meeting. The final voting results for each of the matters submitted to a stockholder vote at the Meeting are set forth below.

• Executive officer departureApr 29, 2026

  On April 24, 2026, Jodi Devlin provided notice to TriSalus Life Sciences, Inc. (the "Company") of her intention to retire from her role as Chief of Clinical Operations, effective October 1, 2026.

• Executive compensation changeApr 7, 2026

  Dr. Marshall will also be eligible for an annual bonus of up to 50% of his annual base salary based on the achievement of financial goals and milestones as determined by the Board of Directors (the "Board"). Following the start of his employment, the Company will recommend to the Board an equity award be granted to Dr. Marshall for 120,000 stock options and 60,000 restricted stock units. In addition, Dr. Marshall will be eligible for an annual equity grant under the Company's Equity Incentive Plan, subject to Board approval.

• Underwriting agreementFeb 20, 2026

  On February 19, 2026, TriSalus Life Sciences, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Lake Street Capital Markets, LLC ("LSCM"), as representative of the underwriters named therein (the "Underwriters"), relating to the public offering (the "Offering") of 9,756,100 shares of common stock of the Company at a price to the public of $4.10 per Share.

Days to cover

4.4

Short interest

3.35M

Avg volume

759.59K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• ALUS presents the 2024 Dave Reid Award to François Allard
  positiveGlobeNewswire Inc.· Oct 18, 2024
• Why Terran Orbital Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
  Benzinga· Sep 19, 2023